dsm-firmenich sues Chinese parties over patented biotechnological sclareol production
- Litigation filed at the Xiong’An New District Court of Hebei Province, China.
- Defendants include multiple Chinese entities, among them a sclareol producer and a research institute.
- Allegation: unauthorized use of dsm‑firmenich’s patent to produce sclareol, an intermediate for amber ingredients such as Ambrox® Super.
- dsm‑firmenich seeks court orders to stop the use and to obtain compensation for the alleged infringement.
Case filed in China
dsm-firmenich has initiated patent infringement litigation before the Xiong’An New District Court of Hebei Province, China, against multiple Chinese entities, including a sclareol producer and a research institute. The petition alleges unauthorized use of dsm-firmenich’s patent for the production of sclareol, a valuable intermediate in the production of amber ingredients such as Ambrox® Super.
Remedies sought
The company requests that the Court order the defendants to cease the unauthorized use of the patented technology and to provide compensation for the alleged infringement.
Company statement on IP
Amaury Roquette, Executive Vice President Perfumery & Beauty Ingredients at dsm-firmenich, said the company holds a "robust portfolio of proprietary technologies" and that its "well-established intellectual property (IP) position, including patent rights and deep know-how on sclareol and related derivatives, enables us to ensure that our customers continue to benefit from our innovation, quality and expertise in amber-type fragrance ingredients." He added the company "remains committed to taking all necessary legal actions to ensure that the company’s exclusive rights are respected and that its significant investments in innovation as well as our clients are protected globally."
Source: dsm-firmenich
